The Institute of Cancer Research London (ICR) reports on the results of a study that found that artificial intelligence can not only recognize patterns in breast cancer, but also helped to identify five new types of the disease—each matched to different personalized treatments.
This study applied AI and machine learning to gene sequencing and molecular data from breast tumors to reveal crucial differences among cancers that had previously been lumped into one type, as ICR recently announced in a press release.
Led by a ICR team, the study uncovered two of the types were more likely to respond to immunotherapy than others, while one of the breast cancers would more likely to relapse on taxoxifen. The ongoing research design’s purpose now is to test for different types of breast cancer that will be used to select patients for different drugs in clinical trials. The ultimate goal here is to drive personalization into a standard part of treatment. The new research was published in the Journal of NPJ Breast Cancer and could not only hep select treatments for women with breast cancer but also identify new drug targets.
The Institute of Cancer Research, London
A UK-based charity and research institute—funded this study itself from its own charitable donations. ICR is a public research institute and a constituent college of the University of London in London, UK, specializing in oncology.
Founded in 1909 as the research department of the Royal Marsden Hospital, it joined the University of London in 2002. It has been at the forefront of a number of breakthrough discoveries, including that the basic cause of cancer is damage to DNA.
The Centre for Cancer Drug Discover at the ICR
ICR is at the forefront of working to understand cancer’s complexity and evolution is one of the central strategies they are pursuing as part of pioneering research program to combat the ability of cancers to adapt and become resistant. They are in the final push for a £75 million investment for their new Centre for Cancer Drug Discovery to host a world-first program of “anti-evolution” therapies.
Dr. Anguraj Sadanandam, Study Leader
Follow the link below to the source for the remaining press release on how ICR is helping to progress personalization in breast cancer clinical research.